Tower Research Capital (TRC)’s Aardvark Therapeutics AARD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.8K Buy
2,991
+490
+20% +$2.99K ﹤0.01% 3944
2026
Q2
$14.4K Sell
2,501
-2,966
-54% -$13.9K ﹤0.01% 3815
2026
Q1
$20.6K Buy
5,467
+4,656
+574% +$48.3K ﹤0.01% 3459
2025
Q4
$10.6K Sell
811
-374
-32% -$4.67K ﹤0.01% 3729
2025
Q3
$15.7K Sell
1,185
-83
-7% -$936 ﹤0.01% 3524
2025
Q2
$17.1K Buy
+1,268
New +$13.1K ﹤0.01% 3757

Other funds holding AARD

Tower Research Capital (TRC)'s AARD Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its Aardvark Therapeutics (AARD) stake by 20% in Q3 2026, buying an estimated $2.99K and bringing the position to 2,991 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3944.

Tower Research Capital (TRC) first reported a position in AARD in Q2 2025 and has held it in 6 quarters since. The position peaked at $20.6K in Q1 2026. 76 funds tracked by Wall St. Rank hold AARD as of Q3 2026.

  • Tower Research Capital (TRC) held 2,991 shares of Aardvark Therapeutics worth $15.8K as of Q3 2026.
  • Tower Research Capital (TRC) bought 490 Aardvark Therapeutics shares in Q3 2026, an estimated $2.99K.
  • Aardvark Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3944 holding.
  • Tower Research Capital (TRC) first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Tower Research Capital (TRC)'s Aardvark Therapeutics position peaked at $20.6K in Q1 2026.
  • 76 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.